注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Calliditas Therapeutics AB(原名:Pharmalink AB)是一家瑞典的专业制药公司。该公司从事开发和商业化其候选药品Nefecon,用于治疗肾脏炎(免疫球蛋白A肾病)患者。这类患者面临发展为肾功能衰竭的风险。Nefecon源自TARGIT技术,这种技术可以保护含有活性药物的胶囊,使其完整地穿过肠胃,最终到达小肠下端并释放所含物质。Nefeco结合了时间间隔与特定区域内活性物质布地奈德的集中释放。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Elmar J. Schnee | 63 | 2019 | Independent Chairman |
Vladimir Tesar | - | - | Member of Scientific Advisory Board |
Diane L. Parks | 71 | 2019 | Independent Director |
Hérnan Trimarchi | - | - | Member of Scientific Advisory Board |
Henrik Stenqvist | 56 | 2022 | Independent Director |
Brad H. Rovin | - | - | Member of Scientific Advisory Board |
Jürgen Floege | - | - | Member of Scientific Advisory Board |
Jonathan Barratt | - | - | Member of Scientific Advisory Board |
Richard Lafayette | - | - | Member of Scientific Advisory Board |
Hilde Furberg | 65 | 2014 | Independent Non-Executive Director |
Elisabeth Bjork | 62 | 2022 | Independent Director |
Hong Zhang | - | - | Member of Scientific Advisory Board |
Frederick W. Driscoll | 72 | 2023 | Director |
Heather N. Reich | - | - | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核